Effectiveness of highly purified urofollitropin treatment in patients with idiopathic azoospermia before testicular sperm extraction

Cocci, Andrea; Cito, G.; Russo, Giorgio Ivan; Falcone, Marco; Capece, Marco; Timpano, M.; Camera, P. Della; Morselli, Simone; Tasso, Giovanni; Morelli, Girolamo; Morgia, Giuseppe; Minervini, Andrea; Serni, Sergio; Carini, Marco; Natali, Alessandro; Gacci, Mauro

doi:10.5301/uj.5000253

Cited by 20 publications

(16 citation statements)

References 9 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given that mTESE was not performed in these men, it is possible that the study results are reflective of some degree of sampling bias. Similar to previous studies, the investigators proposed the mechanism of action to be increased activity at the FSH receptor affecting both Sertoli cells and spermatogonial stem cells (4).…”

supporting

confidence: 69%

“…Previous studies that have analyzed the effects of therapeutic FSH on sperm retrieval rates (SRR) have been limited in size, duration, randomization, presence of a control group, and inclusion/exclusion criteria (1,3,4). A nonrandomized prospective trial by Aydos et al (3) demonstrated that 75 IU of FSH administered three times weekly to azoospermic men significantly increased SRR at the time of microdissection testicular sperm extraction (mTESE) compared with control patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Is it time to revisit follicle-stimulating hormone therapy in men with azoospermia?

Fantus

Halpern

Brannigan

2021

Fertility and Sterility

View full text Add to dashboard Cite

supporting

confidence: 69%

mentioning

confidence: 99%

Is it time to revisit follicle-stimulating hormone therapy in men with azoospermia?

Fantus

Halpern

Brannigan

2021

Fertility and Sterility

View full text Add to dashboard Cite

“…Given the (presumed) primary testicular inability to produce sperms in such cases, there is no clear rationale in proposing a further FSH stimulation in the presence of serum FSH levels above the normal range. However, some studies reported an increased rate of sperms extracted after TESE/micro-TESE in men with non-obstructive azoospermia treated with clomiphene citrate [149], hCG [150], hMG [149], and FSH [151,152]. These findings would suggest that the minimal, residual spermatogenic activity could be stimulated even in case of elevated serum FSH levels, at least in some patients.…”

Section: Therapeutic Options To Improve Sperm Productionmentioning

confidence: 99%

Follicle-Stimulating Hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles

Santi

Crépieux

Reiter

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Human reproduction is regulated by the combined action of the follicle-stimulating hormone (FSH) and the luteinizing hormone (LH) on the gonads. Although FSH is largely used in female reproduction, in particular in women attending assisted reproductive techniques to stimulate multi-follicular growth, its efficacy in men with idiopathic infertility is not clearly demonstrated. Indeed, whether FSH administration improves fertility in patients with hypogonadotropic hypogonadism, the therapeutic benefit in men presenting alterations in sperm production despite normal FSH serum levels is still unclear. In the present review, we evaluate the potential pharmacological benefits of FSH administration in clinical practice. Methods: This is a narrative review, describing the FSH physiological role in spermatogenesis and its potential therapeutic action in men. Results: The FSH role on male fertility is reviewed starting from the physiological control of spermatogenesis, throughout its mechanism of action in Sertoli cells, the genetic regulation of its action on spermatogenesis, until the therapeutic options available to improve sperm production. Conclusion: FSH administration in infertile men has potential benefits, although its action should be considered by evaluating its synergic action with testosterone, and well-controlled, powerful trials are required. Prospective studies and new compounds could be developed in the near future.

show abstract

“…Controlled ovarian hyperstimulation (COH) technology aims to stimulate ovulation with drugs to obtain an appropriate number of healthy fertilizable oocytes (10). The drugs commonly used in the clinic include the gonadotropin drug urofollitropin, the pituitary down-regulation medicine triptorelin acetate, and the ovarian stimulation drug hCG (11)(12)(13).…”

mentioning

confidence: 99%

MTHFR C677T polymorphism is associated with follicle-stimulating hormone levels and controlled ovarian hyperstimulation response: a retrospective study from the clinical database

Zeng

Wang

et al. 2019

Fertility and Sterility

View full text Add to dashboard Cite

This genetic association study included 722 infertile women who received the standard long treatment protocol with accessible and complete electronic medical records. Intervention(s): None. Main Outcome Measure(s): The clinical parameters were obtained from the Intravenous Infusion Safety Evaluation center. Result(s): Basal FSH levels in the TT group were significantly higher than those of the CC group. The FSH levels after down-regulation in the TT group were higher than those of CC/CT genotypes. The TT genotype patients received significantly higher total doses of GnRH agonist and FSH compared with CC/CT genotypes, whereas the total dose of hCG was higher in the CT genotypes compared with the CC/ TT genotypes. Further association analysis between hormone levels and COH outcomes indicated significantly negative correlation of basal FSH levels with antral follicle count and number of oocytes as well as the down-regulation FSH levels with the number of metaphase II oocytes and oocytes. Conclusion(s):The MTHFR C677T polymorphism was associated with high doses of ovarian stimulation medications, as well as higher FSH levels. The negative correlation between FSH levels and the number of oocytes suggested that C677T polymorphism may play a role in the poor prognosis of COH oocytes. This needs to be studied in future prospective studies with longer follow-up. (Fertil Steril Ò 2019;111:982-90. Ó2019 by American Society for Reproductive Medicine.) El resumen está disponible en Español al final del artículo.

show abstract

Effectiveness of highly purified urofollitropin treatment in patients with idiopathic azoospermia before testicular sperm extraction

Abstract: FSH treatment showed greater efficacy rather than control by increasing the rate of PR and FR in azoospermic patients who underwent TESE.

Cited by 20 publications

References 9 publications

Is it time to revisit follicle-stimulating hormone therapy in men with azoospermia?

Is it time to revisit follicle-stimulating hormone therapy in men with azoospermia?

Follicle-Stimulating Hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles

MTHFR C677T polymorphism is associated with follicle-stimulating hormone levels and controlled ovarian hyperstimulation response: a retrospective study from the clinical database

Contact Info

Product

Resources

About